Medical AI Company Lunit Files Preliminary Review for KOSDAQ Listing
[Asia Economy Reporter Chunhee Lee] Medical artificial intelligence (AI) company Lunit has filed for a preliminary review for listing on KOSDAQ.
The Korea Exchange announced on the 26th that Lunit has filed for a preliminary review for listing. NH Investment & Securities is the lead underwriter.
Lunit is a deep learning medical AI company established in 2013. It develops and provides solutions that contribute to the diagnosis and treatment of diseases, including cancer, through AI based on deep learning technology.
In June, Lunit received the highest AA rating from multiple professional evaluation agencies in the technical evaluation for KOSDAQ technology special listing. Lunit is the only healthcare company to have received all AA ratings in the technical evaluation.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Lunit raised 5.8 billion KRW through Series A in 2015-2016, 21.8 billion KRW through Series B in 2018-2019, 30 billion KRW through Series C (Tranche A) in 2019, and 30 billion KRW through Series C (Tranche B) in 2021. On the 24th, it also successfully secured 72 billion KRW in pre-IPO investment. Having raised a total of approximately 160 billion KRW, these funds will be used as operating capital for R&D of AI products and global market expansion.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
